The management of breast cancer is a complex and rapidly advancing field of oncology where treatment has become increasingly personalized based on the tumor’s specific molecular characteristics. A pharmacist’s role is critical in managing this disease, requiring a deep understanding of traditional chemotherapy, hormonal agents, and sophisticated targeted therapies. As detailed in the Patient Care 2 curriculum, this knowledge is fundamental to providing safe and effective care. This quiz will test your knowledge on the pharmacotherapeutic principles guiding the treatment of ER-positive, HER2-positive, and triple-negative breast cancer.
1. A breast cancer tumor is classified based on the status of which three key receptors?
- a. Insulin Receptor, Glucagon Receptor, and Somatostatin Receptor
- b. Estrogen Receptor (ER), Progesterone Receptor (PR), and Human Epidermal Growth Factor Receptor 2 (HER2)
- c. Dopamine Receptor, Serotonin Receptor, and Histamine Receptor
- d. Mu-Opioid Receptor, Kappa-Opioid Receptor, and Delta-Opioid Receptor
Answer: b. Estrogen Receptor (ER), Progesterone Receptor (PR), and Human Epidermal Growth Factor Receptor 2 (HER2)
2. What is the first-line endocrine therapy for a premenopausal woman with ER-positive breast cancer?
- a. An aromatase inhibitor like anastrozole.
- b. A SERM like tamoxifen.
- c. A GnRH agonist like leuprolide alone.
- d. A CDK 4/6 inhibitor.
Answer: b. A SERM like tamoxifen.
3. Aromatase inhibitors (e.g., anastrozole, letrozole) are a standard treatment for postmenopausal women with ER-positive breast cancer. What is their mechanism of action?
- a. They directly block the estrogen receptor in breast tissue.
- b. They block the peripheral conversion of androgens to estrogens.
- c. They cause destruction of the ovaries.
- d. They inhibit the HER2 receptor.
Answer: b. They block the peripheral conversion of androgens to estrogens.
4. Trastuzumab (Herceptin) is a monoclonal antibody used to treat which subtype of breast cancer?
- a. ER-positive only
- b. PR-positive only
- c. Triple-negative
- d. HER2-positive
Answer: d. HER2-positive
5. A major dose-limiting and potentially irreversible toxicity associated with anti-HER2 therapies like trastuzumab is:
- a. Nephrotoxicity
- b. Hepatotoxicity
- c. Cardiotoxicity (left ventricular dysfunction)
- d. Peripheral neuropathy
Answer: c. Cardiotoxicity (left ventricular dysfunction)
6. The “Management of Breast Cancer” is a specific learning module in which course?
- a. PHA5782C Patient Care 2
- b. PHA5104 Sterile Compounding
- c. PHA5703 Pharmacy Law and Ethics
- d. PHA5787C Patient Care 5
Answer: a. PHA5782C Patient Care 2
7. A patient taking tamoxifen should be counseled about an increased risk of:
- a. Osteoporosis
- b. Venous thromboembolism (VTE) and endometrial cancer.
- c. Myocardial infarction.
- d. Severe nausea and vomiting.
Answer: b. Venous thromboembolism (VTE) and endometrial cancer.
8. Palbociclib, ribociclib, and abemaciclib are oral medications used for metastatic HR-positive breast cancer that work by inhibiting:
- a. EGFR
- b. VEGF
- c. Cyclin-dependent kinases 4 and 6 (CDK 4/6)
- d. PARP
Answer: c. Cyclin-dependent kinases 4 and 6 (CDK 4/6)
9. Which of the following best describes triple-negative breast cancer (TNBC)?
- a. It is positive for ER, PR, and HER2 receptors.
- b. It is negative for ER, PR, and HER2 receptors.
- c. It is the easiest form of breast cancer to treat.
- d. It is primarily treated with endocrine therapy.
Answer: b. It is negative for ER, PR, and HER2 receptors.
10. A common side effect of aromatase inhibitors that requires monitoring and counseling is:
- a. An increased risk of VTE.
- b. An increased risk of bone loss and arthralgias (joint pain).
- c. Endometrial cancer.
- d. Severe diarrhea.
Answer: b. An increased risk of bone loss and arthralgias (joint pain).
11. The “Pharmacology of Anticancer Therapeutics,” including hormonal agents, is a topic within the Patient Care 2 curriculum.
- a. True
- b. False
Answer: a. True
12. Tamoxifen is a prodrug that is converted to its more active metabolite, endoxifen, by which CYP enzyme?
- a. CYP3A4
- b. CYP1A2
- c. CYP2D6
- d. CYP2C9
Answer: c. CYP2D6
13. A patient taking tamoxifen should avoid which of the following antidepressants due to a significant drug interaction?
- a. Mirtazapine
- b. Citalopram
- c. Paroxetine (a potent CYP2D6 inhibitor)
- d. Venlafaxine
Answer: c. Paroxetine (a potent CYP2D6 inhibitor)
14. Ado-trastuzumab emtansine (Kadcyla) is what type of targeted therapy?
- a. A small molecule tyrosine kinase inhibitor.
- b. A monoclonal antibody.
- c. An antibody-drug conjugate (ADC).
- d. A CDK 4/6 inhibitor.
Answer: c. An antibody-drug conjugate (ADC).
15. Counseling patients on the management of chemotherapy-induced nausea and vomiting (CINV) is a key role for a pharmacist.
- a. True
- b. False
Answer: a. True
16. Pertuzumab is often used in combination with trastuzumab for HER2+ breast cancer because it:
- a. Reduces the cardiotoxicity of trastuzumab.
- b. Binds to a different domain of the HER2 receptor, providing dual blockade.
- c. Is an oral formulation.
- d. Is a cheaper alternative.
Answer: b. Binds to a different domain of the HER2 receptor, providing dual blockade.
17. The basic principles of cancer treatment are a topic within the Patient Care 2 curriculum.
- a. True
- b. False
Answer: a. True
18. Adjuvant therapy for breast cancer refers to treatment given:
- a. Before surgery to shrink the tumor.
- b. After primary treatment like surgery to eliminate micrometastatic disease.
- c. For metastatic disease to prolong life.
- d. In place of surgery.
Answer: b. After primary treatment like surgery to eliminate micrometastatic disease.
19. What is the most common route of administration for trastuzumab?
- a. Oral
- b. Intramuscular
- c. Intravenous
- d. Transdermal
Answer: c. Intravenous
20. An active learning session on oncology is part of the Patient Care 2 course.
- a. True
- b. False
Answer: a. True
21. A patient with a BRCA gene mutation is at high risk for breast cancer. If they develop metastatic TNBC, they may be a candidate for which class of targeted therapy?
- a. Aromatase inhibitors
- b. PARP inhibitors
- c. CDK 4/6 inhibitors
- d. Anti-HER2 therapy
Answer: b. PARP inhibitors
22. A common chemotherapy regimen for early-stage breast cancer is “AC,” which stands for:
- a. Anastrozole and Cyclophosphamide
- b. Adriamycin (doxorubicin) and Cyclophosphamide
- c. Abemaciclib and Capecitabine
- d. Aspirin and Clopidogrel
Answer: b. Adriamycin (doxorubicin) and Cyclophosphamide
23. The “Hormonal Agents” lecture is part of the oncology module in Patient Care 2.
- a. True
- b. False
Answer: a. True
24. An active learning session on oncology is part of which course?
- a. PHA5782C Patient Care 2
- b. PHA5163L Professional Skills Lab 3
- c. PHA5781 Patient Care I
- d. PHA5787C Patient Care 5
Answer: a. PHA5782C Patient Care 2
25. A pharmacist’s role in managing breast cancer therapy includes:
- a. Managing supportive care for chemotherapy side effects.
- b. Verifying the appropriateness of therapy based on receptor status.
- c. Counseling patients on complex hormonal and targeted therapies.
- d. All of the above.
Answer: d. All of the above.
26. Why are aromatase inhibitors only effective in postmenopausal women?
- a. They are too toxic for premenopausal women.
- b. In premenopausal women, the ovaries are the main source of estrogen, and AIs do not block ovarian production.
- c. They only work on the PR receptor.
- d. They have too many drug interactions in younger women.
Answer: b. In premenopausal women, the ovaries are the main source of estrogen, and AIs do not block ovarian production.
27. A patient on trastuzumab therapy must have what monitored regularly?
- a. Liver function tests
- b. Serum creatinine
- c. Left ventricular ejection fraction (LVEF) via echocardiogram.
- d. Complete blood count
Answer: c. Left ventricular ejection fraction (LVEF) via echocardiogram.
28. An active learning session on oncology is part of which course module?
- a. Module 6: Basic Principles of Cancer Treatment
- b. Module 1: Laboratory Diagnostics
- c. Module 3: Introduction to Gram-Positive Bacteria
- d. Module 5: Introduction to Fungal Infections & Antifungals
Answer: a. Module 6: Basic Principles of Cancer Treatment
29. The term “neoadjuvant” therapy means the treatment is given:
- a. After surgery.
- b. Before surgery, to shrink the tumor.
- c. For a different type of cancer.
- d. For at least 5 years.
Answer: b. Before surgery, to shrink the tumor.
30. The management of breast cancer is a lecture within the Patient Care 2 curriculum.
- a. True
- b. False
Answer: a. True
31. Which of the following is a Selective Estrogen Receptor Modulator (SERM)?
- a. Anastrozole
- b. Letrozole
- c. Exemestane
- d. Tamoxifen
Answer: d. Tamoxifen
32. Tamoxifen has what effect on bone tissue?
- a. It acts as an antagonist, increasing fracture risk.
- b. It acts as an agonist, preserving bone mineral density.
- c. It has no effect on bone.
- d. It causes osteonecrosis of the jaw.
Answer: b. It acts as an agonist, preserving bone mineral density.
33. The main reason for using a CDK 4/6 inhibitor in combination with endocrine therapy is to:
- a. Reduce the side effects of the endocrine therapy.
- b. Overcome or delay the development of endocrine resistance.
- c. Treat HER2-positive disease.
- d. Make the therapy cheaper.
Answer: b. Overcome or delay the development of endocrine resistance.
34. For patients with TNBC whose tumors express PD-L1, which class of therapy may be an option?
- a. Endocrine therapy
- b. Anti-HER2 therapy
- c. Immunotherapy (immune checkpoint inhibitors)
- d. Aromatase inhibitors
Answer: c. Immunotherapy (immune checkpoint inhibitors)
35. A key counseling point for a patient on an aromatase inhibitor is:
- a. The need for adequate calcium and vitamin D intake.
- b. The risk of VTE.
- c. The need to take it with food.
- d. The risk of endometrial cancer.
Answer: a. The need for adequate calcium and vitamin D intake.
36. Doxorubicin is an anthracycline chemotherapy agent with a known cumulative lifetime dose limit due to the risk of:
- a. Nephrotoxicity
- b. Cardiotoxicity
- c. Neurotoxicity
- d. Hepatotoxicity
Answer: b. Cardiotoxicity
37. The choice between tamoxifen and an aromatase inhibitor for a postmenopausal woman depends on:
- a. The patient’s side effect tolerance and comorbidity profile.
- b. The stage of the cancer.
- c. The patient’s preference after a discussion of risks and benefits.
- d. All of the above.
Answer: d. All of the above.
38. The lecture “Introduction to Breast Cancer” is part of which course?
- a. PHA5782C Patient Care 2
- b. PHA5163L Professional Skills Lab 3
- c. PHA5781 Patient Care I
- d. PHA5787C Patient Care 5
Answer: a. PHA5782C Patient Care 2
39. A patient is receiving a chemotherapy regimen known to be highly emetogenic. The pharmacist should ensure they receive appropriate prophylaxis for:
- a. Diarrhea
- b. Chemotherapy-induced nausea and vomiting (CINV)
- c. Anemia
- d. Neutropenia
Answer: b. Chemotherapy-induced nausea and vomiting (CINV)
40. An active learning session covering oncology is part of which course?
- a. PHA5782C Patient Care 2
- b. PHA5163L Professional Skills Lab 3
- c. PHA5781 Patient Care I
- d. PHA5787C Patient Care 5
Answer: a. PHA5782C Patient Care 2
41. The term “HER2-positive” means the cancer cells have:
- a. An absence of the HER2 receptor.
- b. An over-expression of the HER2 receptor.
- c. A mutation in the estrogen receptor.
- d. A mutation in the BRCA gene.
Answer: b. An over-expression of the HER2 receptor.
42. Which of the following is an irreversible, steroidal aromatase inhibitor?
- a. Anastrozole
- b. Letrozole
- c. Exemestane
- d. Tamoxifen
Answer: c. Exemestane
43. A pharmacist’s role in breast cancer therapy is critical because:
- a. The regimens are complex and have significant toxicities.
- b. Supportive care management is essential for maintaining quality of life.
- c. Targeted therapies require an understanding of biomarkers.
- d. All of the above.
Answer: d. All of the above.
44. What is the standard duration of adjuvant endocrine therapy for most women with early-stage HR+ breast cancer?
- a. 1 year
- b. 2 years
- c. At least 5 years, and often extended to 10 years.
- d. Lifelong.
Answer: c. At least 5 years, and often extended to 10 years.
45. Which of the following is NOT a common side effect of chemotherapy?
- a. Myelosuppression
- b. Nausea and vomiting
- c. Alopecia
- d. Increased energy
Answer: d. Increased energy
46. “Personalized medicine” in oncology is exemplified by:
- a. Giving every patient the same chemotherapy regimen.
- b. Selecting a therapy (like an EGFR or HER2 inhibitor) based on the specific molecular characteristics of a patient’s tumor.
- c. Dosing based on weight only.
- d. Using only oral medications.
Answer: b. Selecting a therapy (like an EGFR or HER2 inhibitor) based on the specific molecular characteristics of a patient’s tumor.
47. The pharmacology of hormonal agents is covered in the Patient Care 2 curriculum.
- a. True
- b. False
Answer: a. True
48. An active learning session on oncology is part of which course module?
- a. Module 6: Basic Principles of Cancer Treatment
- b. Module 1: Laboratory Diagnostics
- c. Module 3: Introduction to Gram-Positive Bacteria
- d. Module 5: Introduction to Fungal Infections & Antifungals
Answer: a. Module 6: Basic Principles of Cancer Treatment
49. The overall management of breast cancer requires:
- a. A single physician.
- b. A multidisciplinary team including surgeons, oncologists, radiation oncologists, and pharmacists.
- c. Only a pharmacist.
- d. A focus on chemotherapy alone.
Answer: b. A multidisciplinary team including surgeons, oncologists, radiation oncologists, and pharmacists.
50. The ultimate goal of learning about the management of breast cancer is to:
- a. Be able to safely and effectively manage complex pharmacotherapy to improve patient survival and quality of life.
- b. Memorize all the chemotherapy acronyms.
- c. Pass the oncology exam.
- d. Become a surgical oncologist.
Answer: a. Be able to safely and effectively manage complex pharmacotherapy to improve patient survival and quality of life.
